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Introduction 
Childhood paracetamol (acetaminophen) ingestion with the inherent risk of 
hepatotoxicity is a major medical problem in most parts of the world. The issue of 
over-the-counter medications leading to unintentional ingestions in children and the 
importance of child-resistant closures for liquid paracetamol preparations has already 
been addressed in previous studies [1, 2]. At the beginning of 2002, an over-the-
counter orodispersible paracetamol formulation was licensed in Switzerland. The aim 
of the present study was to investigate the risk of high-dose ingestion of 
orodispersible fast disintegrating paracetamol tablets in children. 
 
Methods 
Data acquisition and Inclusion criteria 
The Swiss Toxicological Information Centre (STIC) collects specific informations from 
laypersons and detailed clinical reports from physicians and hospitals about 
poisoning cases, by means of an in-house computer-based and structured data-
recording and analysis system [3]. At the time of the initial phone call clinical 
information is obtained such as age and gender of the patient, circumstances of 
intoxication, ingested doses of all substances involved, symptoms and causality. 
These data are verified and supplemented by information from discharge letters and 
laboratory reports where available. We performed a retrospective single-centre 
analysis of all cases reported to our centre of accidental self-administration of solid or 
orodispersible 500 mg paracetamol tablets occurring in children up to 6 years during 
the period June 2003 - August 2009. Only cases with acute ingestion of a single 
substance (paracetamol) and available information on the ingested dose were 
included.  
 
Statistical evaluation 
Statistical analysis was performed with SPSS software (Version 17.0; SPSS Inc., 
Chicago, IL, USA). Between-group comparisons were made using the Mann-Whitney 
U-test (2-tailed). 
 
Results 
A search of our database yielded 187 pediatric cases with ingestion of solid 500 mg 
paracetamol tablets (group 1) and 16 pediatric cases with ingestion of orodispersible 
 3
500 mg tablets (group 2) which were fulfilling the inclusion criteria. A comparison of 
the two groups in terms of age of the patients, number of ingested tablets and 
ingested dose is shown in table 1. The mean ingested dose in the orodispersible 
tablet group was 59% higher than in the solid tablet group, although the difference 
did not reach statistical significance (p=0.085). In 9 patients (4.8%) in the solid tablet 
group and 1 patient (6.25%) in the orodispersible tablet group, primary 
gastrointestinal decontamination with oral activated charcoal was recommended 
because paracetamol intake was between 150 and 200 mg/kg body weight. In 23 
patients (12.3%) in the solid tablet group and 4 patients (25%) in the orodispersible 
tablet group, hospitalization for N-acetylcysteine (NAC) treatment was recommended 
because paracetamol intake was ≥ 200 mg/kg body weight. Overall, administration of 
oral activated charcoal and/or NAC because of ingestion of a potentially hepatotoxic 
paracetamol dose, was recommended in 32 patients (7.1%) in the solid tablet group 
and in 5 patients (31%) in the orodispersible tablet group. 
The analysis of the clinical course of paracetamol-poisoned children was not the 
focus of this study. However, among the cases where such information was 
available, no symptoms or signs of hepatotoxicity were observed and patients 
remained asymptomatic, except for two patients among those hospitalized for NAC 
administration, who showed mild gastrointestinal symptoms such as nausea and 
vomiting (one in the orodispersible tablet group and one in the solid tablet group). 
 
Discussion 
Possible factors leading to ingestion of higher paracetamol doses with the 
orodispersible formulations are the rapid disintegration of the tablets within seconds 
of contact with saliva, the pleasant feeling in the mouth, the masked bitter 
paracetamol taste and the candy-like aspect which may encourage consumption by 
children [4]. Further factors not directly associated with the orodispersible 
formulation, as lack of child-resistant closure and blister safety packaging, lack of 
vigilance by parents and caregivers in the storage of medications and availability of 
adult-strength tablets may have acted as confounders which we were unable to 
control for in analyses, and possibly contributed to increasing the risk of high-dose 
paracetamol ingestion in the orodispersible formulation group. 
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Study limitations 
The interpretation of our findings is limited by the retrospective nature of the study 
design. In addition, data from poison control centres are subject to reporting bias, as 
we do not know the percentage of cases reported to the STIC. Furthermore, the 
decision to only include patients who ingested paracetamol alone, led to small case 
numbers. 
 
Conclusions 
This study highlighted the problem of the availability of orodispersible paracetamol 
formulations, which may represent an important risk factor for severe paracetamol 
poisoning in children. Over-the-counter availability may contribute to increasing the 
use of this galenic formulation and eventually the number of poisonings in children. 
Further studies with larger case numbers are required to confirm our findings. 
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Table 1.  
Comparison of cases with solid versus orodispersible paracetamol tablets ingestion 
 
           
Solid  
paracetamol 
n = 187 
Orodispersible  
paracetamol 
n = 16 
 
P-value
Age (years)                              mean ± SD 
 (range)                                    median 
2.3 ± 0.92 (0.8-6)  
2 
3 ± 1.21 (1.5-5)  
2.5 
0.046 
Number of ingested tablets     mean ± SD 
 (range)                                    median 
2.5 ± 1.96 (0.3-8)  
2 
4.6 ± 3.76 (1-14)  
4 
0.057 
 
Ingested dose in mg/kg           mean ± SD 
 (range)                                    median 
98.7 ± 77.7 (8.3-444) 
71 
157.3 ± 147.6 (29.4-538) 
100 
0.085 
 
 
